Compare

Tarsus Pharmaceuticals, Inc. vs Twist Bioscience Corp vs Immunocore Holdings plc vs ADMA Biologics, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearTarsus Pharmaceuticals, Inc.
TARS
Twist Bioscience Corp
TWST
Immunocore Holdings plc
IMCR
ADMA Biologics, Inc.
ADMA
Year ended2025-12-312026-09-302025-12-312025-12-31
Revenue$451.36M$459.43M$400.02M$510.17M
Revenue growth (YoY)+146.7%+22.0%+29.0%+19.6%
Gross marginn/a52.4% (computed)n/a57.4%
Operating margin-15.7%-30.4%-11.3%37.5%
Net margin-14.7%-28.3%-8.9%28.8%
Net income-$66.42M-$130.20M-$35.51M$146.93M
EPS (Diluted)-$1.59-$2.08-$0.71$0.60
Operating cash flow-$12.45M-$41.43M-$10.71M$50.40M
Free cash flow-$22.31M-$89.01M-$15.05M$27.82M
Cash & equivalents$183.64M$533.99M$467.71M$87.63M
Total assets$562.16M$1.12B$1.07B$624.24M
Total liabilities$218.73M$233.79M$686.24M$146.92M
Shareholders' equity$343.43M$888.02M$381.03M$477.32M
Return on year-end equity-19.3%-14.7%-9.3%30.8%
Shares outstanding42.55M67.81M50.69M237.87M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearTarsus Pharmaceuticals, Inc.Twist Bioscience CorpImmunocore Holdings plcADMA Biologics, Inc.
Latest$451.36M
Ended 2025-12-31
$459.43M
Ended 2026-09-30
$400.02M
Ended 2025-12-31
$510.17M
Ended 2025-12-31
1 year earlier$182.95M
Ended 2024-12-31
$376.57M
Ended 2025-09-30
$310.20M
Ended 2024-12-31
$426.45M
Ended 2024-12-31
2 years earlier$17.45M
Ended 2023-12-31
$312.97M
Ended 2024-09-30
$249.43M
Ended 2023-12-31
$258.21M
Ended 2023-12-31
3 years earlier$25.82M
Ended 2022-12-31
$245.11M
Ended 2023-09-30
$174.36M
Ended 2022-12-31
$154.08M
Ended 2022-12-31
4 years earlier$57.03M
Ended 2021-12-31
$203.56M
Ended 2022-09-30
$36.48M
Ended 2021-12-31
$80.94M
Ended 2021-12-31